RenovoRx Inc (RNXT NASDAQ) stock market data APIs
$0.864
0.04(4.6%)
as of May 8, 2026
Try our APIs with
free plan!
RenovoRx Inc Financial Data Overview
Price chart is built with
Anychart
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Prev. Close
0.864
Open
0.9028
High
0.9029
Low
0.8579
52 wk Range
0.701-1.45
Market Cap
38 908 K
Shares Outstanding
45 053 K
Revenue
1 123 K
EPS
-0.0803
Beta
0.996
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with RenovoRx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RenovoRx Inc data using free add-ons & libraries
Get RenovoRx Inc Fundamental Data
RenovoRx Inc Fundamental data includes:
- Net Revenue: 1 123 K
- EBITDA: -12 008 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-01
- EPS/Forecast: -0.0825
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RenovoRx Inc News
New
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.67 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.36 per share a year ago. These figures are adjusted for n...
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer Metabolic Imaging, Used to Ev...
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
RenovoRx, Inc. RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (N...
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapi...
Get RenovoRx Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
